Offered by: Nemours Children's
Location: Delaware Valley
Effect of LDL-Apheresis on Cardiovascular and Renal Outcomes in Focal Segmental Glomerulosclerosis
The purpose of this research is to learn more about how LDL-apheresis may improve focal segmental glomerulosclerosis (FSGS).
Patients who are receiving treatment with the Liposorber® LA-15 System.
Before and after six of your child's Liposorber treatments, blood samples will be collected from the catheter your child has in place to receive the treatments, so they will not be stuck by a needle. At each of these six treatments, we will also take some of the LDL-apheresis effluent, or the part of your child’s blood that is being removed by the device and would not be returned. An arterial stiffness exam will be done before your child’s first LDL-apheresis treatment and again after the last treatment.
Participation will continue throughout the 9 weeks of treatment with the Liposorber® LA-15 System.
Trial Name: Effect of LDL-Apheresis on Cardiovascular and Renal Outcomes in Focal Segmental Glomerulosclerosis
IRB#: 1454348
(800) 354-5690 Email UsLearn more about clinical trials and get answers to questions you might have.
Go to FAQs View All Clinical TrialsNemours has a number of service regions. Selecting your region will help us show you the right contact information and the most relevant content for you.